DGAP-Adhoc: Dermapharm Holding SE: Signing of contract for the acquisition of EUROMED S.A.
DGAP-Ad-hoc: Dermapharm Holding SE / Key word(s): Mergers & Acquisitions
Dermapharm Holding SE: Signing of contract for the acquisition of EUROMED S.A.
18-Nov-2018 / 16:37 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Public disclosure of an insider information according to Article 17 para. 1 of the Regulation (EU) No 596/2014 on market abuse, as amended (Market Abuse Regulation - MAR)
Dermapharm Holding SE: Signing of contract for the acquisition of EUROMED S.A.
Grünwald, November 18, 2018 - Dermapharm Holding SE today signed an agreement to acquire the Spanish company EUROMED S.A.. The purchase agreement is still subject to the approval of the antitrust authorities. Dermapharm's Management Board expects the transaction to be completed at the beginning of 2019. EUROMED S.A. is a leading manufacturer of standardised herbal extracts and natural active ingredients for the pharmaceutical, nutraceutical and cosmetic industries. In 2019, EUROMED S.A. is expected to generate revenues of EUR 70 million and earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 20 million.
Contact
cometis AG
Claudius Krause
Phone: +49 (0)611 - 205855-28
Fax: +49 (0)611 - 205855-66
E-mail: [email protected]
>End of Ad hoc announcement <
18-Nov-2018 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
|
Language: |
English |
Company: |
Dermapharm Holding SE |
|
Lil-Dagover-Ring 7 |
|
82031 Grünwald |
|
Germany |
Phone: |
+49 (0)89 64 86-0 |
E-mail: |
[email protected] |
Internet: |
ir.dermapharm.de |
ISIN: |
DE000A2GS5D8 |
WKN: |
A2GS5D |
Listed: |
Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Stuttgart, Tradegate Exchange |
|
End of Announcement |
DGAP News Service |
747711 18-Nov-2018 CET/CEST
Die wichtigsten Finanzdaten auf einen Blick
|
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023e |
Umsatzerlöse1 |
467,12 |
572,42 |
700,88 |
793,83 |
942,91 |
1.024,78 |
1.105,00 |
EBITDA1,2 |
108,60 |
139,63 |
168,53 |
184,52 |
354,07 |
344,87 |
308,00 |
EBITDA-Marge3 |
23,25 |
24,39 |
24,05 |
23,24 |
37,55 |
33,65 |
|
EBIT1,4 |
92,12 |
107,51 |
119,51 |
136,85 |
298,47 |
243,69 |
200,00 |
EBIT-Marge5 |
19,72 |
18,78 |
17,05 |
17,24 |
31,65 |
23,78 |
18,10 |
Jahresüberschuss1 |
77,74 |
75,23 |
77,81 |
85,93 |
208,90 |
132,62 |
128,00 |
Netto-Marge6 |
16,64 |
13,14 |
11,10 |
10,82 |
22,16 |
12,94 |
11,58 |
Cashflow1,7 |
86,74 |
159,13 |
100,61 |
131,10 |
250,37 |
288,53 |
0,00 |
Ergebnis je Aktie8 |
1,56 |
1,41 |
1,43 |
1,59 |
3,89 |
2,49 |
2,37 |
Dividende8 |
0,00 |
0,77 |
0,80 |
0,88 |
2,17 |
1,05 |
0,00 |
Quelle: boersengefluester.de und Firmenangaben
Geschäftsbericht 2023 - Kostenfrei herunterladen.
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de
Wirtschaftsprüfer: Grant Thornton
|
INVESTOR-INFORMATIONEN |
©boersengefluester.de |
Dermapharm Holding |
WKN |
Kurs in € |
Einschätzung |
Börsenwert in Mio. € |
A2GS5D |
34,160 |
Halten |
1.839,17 |
KGV 2025e |
KGV 10Y-Ø |
BGFL-Ratio |
Shiller-KGV |
12,56 |
21,29 |
0,58 |
19,30 |
KBV |
KCV |
KUV |
EV/EBITDA |
3,76 |
6,37 |
1,79 |
8,17 |
Dividende '22 in € |
Dividende '23e in € |
Div.-Rendite '23e in % |
Hauptversammlung |
1,05 |
1,05 |
3,07 |
05.06.2024 |
Q1-Zahlen |
Q2-Zahlen |
Q3-Zahlen |
Bilanz-PK |
15.05.2024 |
27.08.2024 |
15.11.2023 |
28.03.2024 |
Abstand 60Tage-Linie |
Abstand 200Tage-Linie |
Performance YtD |
Performance 52 Wochen |
-10,19% |
-16,04% |
-19,32% |
-10,11% |
|
|